Avacta Therapeutics, a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces the initiation...
BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced a collaboration with Tempus, a technology...
Tempus, a leader in artificial intelligence and precision medicine, announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with...
Tempus, a leader in artificial intelligence and precision medicine, announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device...
Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are...
